Clinical trial
Efficacy and Safety Study of Folfox4 Chemotherapy Regimen to Prevent Early Recurrence of Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus Following Curative Resection
NCT02813096 is registered in ClinicalTrials.gov with Guangxi Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety Study of Folfox4 Chemotherapy Regimen to Prevent Early Recurrence of Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus Following Curative Resection
- Lead sponsor
- Guangxi Medical University
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- October 31, 2016
- Completion date
- July 31, 2018
- Enrollment
- 500 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.